Founded in 2015, Airdoc adheres to the brand mission “More Intelligence Better Care”. Powered by the proprietary Wanyu® AI Medical Large Model, the company has independently developed three core AI product lines: Retina-AI, PBM-AI, and Neuro-AI. Airdoc delivers intelligent healthcare solutions covering chronic disease early screening and management, myopia prevention and control, stress monitoring, as well as strabismus and amblyopia treatment, making professional AI healthcare accessible to all.

Airdoc’s AI products are widely applied in graded hospitals, community clinics, physical examination centers, optometry centers, insurance institutions and pharmacies worldwide. Backed by over 55 international publications and more than 300 patents, the company has obtained EU CE and US FDA medical device certifications, with business coverage across 55 countries and regions globally. Retina-AI has provided AI retinal screening services for over 40 million people worldwide, representing China’s grassroots AI medical achievements at the 79th World Health Assembly.

Listed on the Hong Kong Stock Exchange in 2021 (02251.HK), Airdoc is recognized as the first medical AI listed company. It is a global pioneer in retinal imaging AI and AI photobiomodulation (AI-PBM) myopia control. Airdoc holds China’s first Class III medical device certificate for AI-assisted fundus chronic disease diagnosis, and has received top industry honors including the Wu Wenjun Artificial Intelligence Science and Technology Progress Award and the Special Grand Prize of the Geneva International Exhibition of Inventions.

Retina-AI:Built on Wanyu® AI, Retina-AI enables accurate assessment of 55 fundus diseases and systemic chronic disease risks such as myocardial infarction, stroke and Alzheimer’s disease through a single fundus photograph.

PBM-AI:Driven by Wanyu® AI, PBM-AI builds a full-process precision myopia control system, covering AI risk prediction, light therapy adaptation, intervention and continuous efficacy tracking. Equipped with innovative LED light source and annular spot technology, the PBM-LED® Vision Rehabilitation Device provides precise and safe myopia prevention solutions for children.

Neuro-AI:Based on Wanyu® AI, Neuro-AI adopts visual stimulation holographic autonomic nerve technology and AI eye-tracking technology. It supports non-contact detection and scientifically quantifies five key indicators within 90 seconds: psychological stress, physical stress, stress resilience, autonomic nerve balance and activity.